Short answer
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). $200M five-year senior secured term facility, providing Kestra with substantial growth and acquisition financing capacity.
KESTRA MEDICAL TECHNOLOGIES, LTD. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $200M five-year senior secured term facility, providing Kestra with substantial growth and acquisition financing capacity
- $75M Tranche A funded July 10, 2026; approximately $20M net proceeds after costs and repayment of prior debt
- Additional $25M Tranche B available through July 31, 2027, subject to limited conditions
- $50M Tranche C contingent on $150M trailing-twelve-month revenue, exercisable through June 30, 2028
- $50M uncommitted acquisition tranche requires lender approval, increasing potential financing but not guaranteed availability
Item 1.02 · Termination of a Material Definitive Agreement
- Prior Loan Agreement with Perceptive Credit Holdings IV terminated upon July 10, 2026 Loan Agreement
- Borrower’s payment and other obligations fully paid and discharged
- Prior Lender’s security interests in company assets and property released
- Refinancing removed the prior lender’s claims against company collateral
Item 2.02 · Results of Operations and Financial Condition
- Fiscal-quarter results covered period ended April 30, 2026
- Press release issued July 14, 2026
- Financial figures and management commentary contained in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- FY26 revenue $95.1M, up 59%, with ASSURE prescriptions up 57% to 20,720
- Gross margin expanded to 51.4% from 40.5%, signaling improving unit economics and reimbursement mix
- FY26 GAAP net loss widened to $131.6M, while adjusted EBITDA loss increased to $87.0M
- Cash, cash equivalents, and investments totaled $262.2M, but operating cash use reached $81.7M
- FY27 revenue guidance of $137M implies 44% growth, raising execution expectations for commercial expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other KESTRA MEDICAL TECHNOLOGIES, LTD. 8-K filings
Get the next KMTS 8-K as it lands
Follow KMTS for push alerts, or ask the research agent what this filing means.